CoChat

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Open access
Kanwal, Fasiha, Kramer, Jennifer R., Li, Liang, Yang, Yu-Xiao, Cao, Yumei, Yu, Xian, Samuel, Ronald, Ali, Basim, Desiderio, Roxanne, Cholankeril, George, Bajaj, Mandeep, El-Serag, Hashem B., Asch, Steven M. · 2024 · JAMA Internal Medicine
Cited by 156

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing cause of cirrhosis. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are effective in improving liver inflammation in patients with MASLD. Objective: To determine whether use of GLP-1 RAs is associated with lower risk of developing cirrhosis and its complications, including decompensation and hepatocellular cancer (HCC), among patients with MASLD. Design, Setting, and Participants: This retrospective cohort study with an active comparator, new-user design used data from the national Veterans Health Administration Corporate Data Warehouse and Central Cancer Registry. Patients with MASLD and diabetes who were seen at 130 Veterans Health Administration hospitals and associated ambulatory clinics and who initiated either a GLP-1 RA or dipeptidyl peptidase 4 inhibitor (DPP-4i) between January 1, 2006, and June 30, 2022, were included. Patients were followed up from baseline until one of the study outcomes or the end of the study period (December 31, 2022), whichever came first. Exposures: Each GLP-1 RA new user was propensity score matched in 1:1 ratio to a patient who initiated a DPP-4i during the same month. Separate analyses were conducted among patients without and with cirrhosis at baseline. Main Outcomes and Measures: For patients without cirrhosis, the primary outcome was progression to cirrhosis defined by validated diagnoses codes or a noninvasive marker of liver fibrosis, and secondary outcomes were cirrhosis complications defined both as a composite and individual complications, including decompensation, HCC, or liver transplant, and all-cause mortality. For patients with cirrhosis, the primary outcome was a composite outcome of cirrhosis complications, and secondary outcomes were decompensation, HCC, and all-cause mortality. Results: Of 16 058 patients who initiated GLP-1 RAs, 14 606 did not have cirrhosis (mean [SD] age, 60.56 [10.31] years; 13 015 [89.1%] male), and 1452 had cirrhosis (mean [SD] age, 66.99 [7.09] years; 1360 [93.7%] male) at baseline. These patients were matched to an equal number of patients who initiated a DPP-4i. In patients without cirrhosis, GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of cirrhosis (9.98 vs 11.10 events per 1000 person-years; hazard ratio [HR], 0.86; 95% CI, 0.75-0.98). Similar results were seen for the secondary outcomes. GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of the composite outcome of cirrhosis complications (1.89 vs 2.55 events per 1000 person-years; HR, 0.78; 95% CI, 0.59-1.04) and mortality (21.77 vs 24.43 events per 1000 person-years; HR, 0.89; 95% CI, 0.81-0.98). There were no associations between GLP-1 RA use and outcomes in patients with cirrhosis. Conclusions and Relevance: In this cohort study, GLP-1 RA use was associated with a lower risk of progression to cirrhosis and mortality among patients with MASLD and diabetes. The protective association was not seen in patients with existing cirrhosis, underscoring the importance of treatment earlier in the disease course.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2024.4661

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 13

  1. Huang, 2022, Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer., Cell Metab, 34, 969, 10.1016/j.cmet.2022.05.003 · DOI · Paper page
  2. Wester, 2024, Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes., Gut, 73, 835, 10.1136/gutjnl-2023-330962 · DOI
  3. Lapham, 2012, Increased documented brief alcohol interventions with a performance measure and electronic decision support., Med Care, 50, 179, 10.1097/MLR.0b013e3181e35743 · DOI · Paper page
  4. Sohn, 2006, Accuracy and completeness of mortality data in the Department of Veterans Affairs., Popul Health Metr, 4, 2, 10.1186/1478-7954-4-2 · DOI · Paper page
  5. Hernán, 2016, Using big data to emulate a target trial when a randomized trial is not available., Am J Epidemiol, 183, 758, 10.1093/aje/kwv254 · DOI · Paper page
  6. Budd, 2020, Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease., Curr Diab Rep, 20, 59, 10.1007/s11892-020-01349-1 · DOI
  7. Kanwal, 2012, The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs., Gastroenterology, 143, 70, 10.1053/j.gastro.2012.03.038 · DOI
  8. Ruiz, 2018, Validation of an automatically generated screening score for frailty: the care assessment need (CAN) score., BMC Geriatr, 18, 106, 10.1186/s12877-018-0802-7 · DOI
  9. Ruiz, 2018, Association of the CAN score with the FRAIL scale in community dwelling older adults., Aging Clin Exp Res, 30, 1241, 10.1007/s40520-018-0910-4 · DOI
  10. Mahmud, 2022, The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a Veterans Affairs cohort study., Gastroenterology, 163, 257, 10.1053/j.gastro.2022.03.052 · DOI
  11. Wang, 2013, Predicting risk of hospitalization or death among patients receiving primary care in the Veterans Health Administration., Med Care, 51, 368, 10.1097/MLR.0b013e31827da95a · DOI · Paper page
  12. Tarao, 2019, Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta-analytic assessment., Cancer Med, 8, 1054, 10.1002/cam4.1998 · DOI · Paper page
  13. Yen, 2024, Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes., BMC Med, 22, 8, 10.1186/s12916-023-03228-4 · DOI

Cited by

See all 156

Metadata

Authors
Kanwal, F., Kramer, J. R., Li, L., Yang, Y.-X., Cao, Y., Yu, X., Samuel, R., Ali, B., Desiderio, R., Cholankeril, G., Bajaj, M., El-Serag, H. B., & Asch, S. M.
Venue
JAMA Internal Medicine
Published
2024-11-01
Volume
184
Issue
11
Pages
1314
ISSN
2168-6106 (ISSN-L)
OpenAlex
W4402581625
Cited by
156
References
15
FWCI
40.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.